JP2016525352A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016525352A5 JP2016525352A5 JP2016528640A JP2016528640A JP2016525352A5 JP 2016525352 A5 JP2016525352 A5 JP 2016525352A5 JP 2016528640 A JP2016528640 A JP 2016528640A JP 2016528640 A JP2016528640 A JP 2016528640A JP 2016525352 A5 JP2016525352 A5 JP 2016525352A5
- Authority
- JP
- Japan
- Prior art keywords
- manganese
- immunoligand
- disease
- ligand
- expressed
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 claims 8
- 239000003446 ligand Substances 0.000 claims 8
- 229910052748 manganese Inorganic materials 0.000 claims 8
- 239000011572 manganese Substances 0.000 claims 8
- 238000000034 method Methods 0.000 claims 8
- 229910001437 manganese ion Inorganic materials 0.000 claims 6
- 239000001963 growth medium Substances 0.000 claims 5
- 108090000623 proteins and genes Proteins 0.000 claims 4
- 102000004169 proteins and genes Human genes 0.000 claims 4
- 239000002609 medium Substances 0.000 claims 3
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 239000012526 feed medium Substances 0.000 claims 2
- 230000033581 fucosylation Effects 0.000 claims 2
- 230000036039 immunity Effects 0.000 claims 2
- 210000004962 mammalian cell Anatomy 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 241000699802 Cricetulus griseus Species 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 claims 1
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 108060003951 Immunoglobulin Proteins 0.000 claims 1
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 241001465754 Metazoa Species 0.000 claims 1
- 241001529936 Murinae Species 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 230000010261 cell growth Effects 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 230000003013 cytotoxicity Effects 0.000 claims 1
- 231100000135 cytotoxicity Toxicity 0.000 claims 1
- 230000001419 dependent effect Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000004927 fusion Effects 0.000 claims 1
- 238000002649 immunization Methods 0.000 claims 1
- 230000003053 immunization Effects 0.000 claims 1
- 102000018358 immunoglobulin Human genes 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 206010025135 lupus erythematosus Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 210000001672 ovary Anatomy 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN3262/CHE/2013 | 2013-07-23 | ||
| IN3265/CHE/2013 | 2013-07-23 | ||
| IN3262CH2013 | 2013-07-23 | ||
| IN3265CH2013 | 2013-07-23 | ||
| PCT/IB2014/063348 WO2015011660A1 (en) | 2013-07-23 | 2014-07-23 | Methods for controlling fucosylation levels in proteins |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016525352A JP2016525352A (ja) | 2016-08-25 |
| JP2016525352A5 true JP2016525352A5 (cg-RX-API-DMAC7.html) | 2017-06-22 |
| JP6480926B2 JP6480926B2 (ja) | 2019-03-13 |
Family
ID=52392808
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016528640A Active JP6480926B2 (ja) | 2013-07-23 | 2014-07-23 | タンパク質におけるフコシル化レベルを制御するための方法 |
Country Status (19)
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2993186T (pt) | 2008-03-14 | 2019-11-29 | Biocon Ltd | Anticorpo monoclonal e um método do mesmo |
| EP3680344A1 (en) | 2014-12-01 | 2020-07-15 | Amgen Inc. | Process for manipulating the level of glycan content of a glycoprotein |
| US11242401B2 (en) * | 2016-10-21 | 2022-02-08 | Biocon Limited | Monoclonal antibody and a method of use for the treatment of lupus |
| US11530403B2 (en) * | 2016-11-18 | 2022-12-20 | Biocon Limited | Rapid and efficient de-glycosylation of glycoproteins |
| EP4467565A3 (en) | 2016-12-21 | 2025-03-12 | Amgen Inc. | Anti-tnf alpha antibody formulations |
| EP3596225A1 (en) | 2017-03-14 | 2020-01-22 | Amgen Inc. | Control of total afucosylated glycoforms of antibodies produced in cell culture |
| CN111954719B (zh) | 2018-03-26 | 2025-07-18 | 美国安进公司 | 细胞培养物中产生的抗体的总去岩藻糖基化糖型 |
| KR102742590B1 (ko) * | 2018-04-20 | 2024-12-16 | (주)셀트리온 | 당단백질의 푸코실레이션을 조절하는 방법 |
| SG11202100756RA (en) * | 2018-08-10 | 2021-02-25 | Genentech Inc | Cell culture strategies for modulating protein glycosylation |
| HU231514B1 (hu) | 2018-11-07 | 2024-07-28 | Richter Gedeon Nyrt. | Sejttenyészetben előállított rekombináns glikoprotein glikozilációs mintázatának megváltoztatására szolgáló módszer |
| US11634499B2 (en) * | 2018-11-13 | 2023-04-25 | Janssen Biotech, Inc. | Control of trace metals during production of anti-CD38 antibodies |
| JP7469593B2 (ja) * | 2018-12-27 | 2024-04-17 | 東ソー株式会社 | 抗体依存性細胞傷害活性が向上した抗体を製造する方法 |
| CN112779307B (zh) * | 2021-01-11 | 2022-04-19 | 苏州药明生物技术有限公司 | 一种两阶段调节cho表达外源蛋白糖型的方法 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| FI903489A0 (fi) | 1988-11-11 | 1990-07-10 | Medical Res Council | Ligander med en enda sektion, receptorer innehaollande naemnda ligander, foerfaranden foer deras framstaellning samt anvaendning av liganderna och receptorerna. |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| DK1143006T3 (da) | 1995-08-18 | 2008-07-14 | Morphosys Ip Gmbh | Vektorer/DNA-sekvenser fra humane kombinatoriske antistofbiblioteker |
| EP0977991A4 (en) * | 1997-03-03 | 2004-12-15 | Bristol Myers Squibb Co | MONOCLONAL ANTIBODIES FOR HUMAN CD6 |
| DE60301953T2 (de) | 2002-03-05 | 2006-07-27 | Artemis Pharmaceuticals Gmbh | Durch inzucht erzeugte von embryonalen stammzellen abgeleitete mäuse |
| CA2608818A1 (en) | 2005-06-03 | 2006-12-14 | Genentech, Inc. | Method of producing antibodies with modified fucosylation level |
| ES2564790T5 (es) | 2005-12-08 | 2023-08-25 | Amgen Inc | Producción mejorada de glicoproteínas usando manganeso |
| US7846724B2 (en) * | 2006-04-11 | 2010-12-07 | Hoffmann-La Roche Inc. | Method for selecting CHO cell for production of glycosylated antibodies |
| PT2993186T (pt) * | 2008-03-14 | 2019-11-29 | Biocon Ltd | Anticorpo monoclonal e um método do mesmo |
| WO2010141855A1 (en) * | 2009-06-05 | 2010-12-09 | Momenta Pharmaceuticals, Inc. | Methods of modulating fucosylation of glycoproteins |
| CA2794697A1 (en) * | 2010-04-07 | 2011-10-13 | Momenta Pharmaceuticals, Inc. | High mannose glycans |
| EP2809773B1 (en) * | 2012-01-30 | 2020-09-02 | Dr. Reddy's Laboratories Limited | Process of modulating man5 and/or afucosylation content of glycoprotein composition |
-
2014
- 2014-07-23 EA EA201690269A patent/EA201690269A1/ru unknown
- 2014-07-23 NZ NZ716182A patent/NZ716182A/en unknown
- 2014-07-23 HK HK16108338.6A patent/HK1220228A1/zh unknown
- 2014-07-23 MX MX2016001042A patent/MX2016001042A/es unknown
- 2014-07-23 WO PCT/IB2014/063348 patent/WO2015011660A1/en not_active Ceased
- 2014-07-23 EP EP14830053.6A patent/EP3024922A4/en not_active Ceased
- 2014-07-23 EP EP23196563.3A patent/EP4282975A3/en active Pending
- 2014-07-23 PE PE2016000087A patent/PE20160218A1/es not_active Application Discontinuation
- 2014-07-23 KR KR1020167004763A patent/KR102062784B1/ko active Active
- 2014-07-23 BR BR112016001461A patent/BR112016001461A2/pt not_active IP Right Cessation
- 2014-07-23 CN CN201480041292.1A patent/CN105392878A/zh active Pending
- 2014-07-23 CA CA2926967A patent/CA2926967C/en active Active
- 2014-07-23 AU AU2014294618A patent/AU2014294618B2/en active Active
- 2014-07-23 CU CUP2016000008A patent/CU24312B1/xx unknown
- 2014-07-23 JP JP2016528640A patent/JP6480926B2/ja active Active
- 2014-07-23 SG SG11201600067YA patent/SG11201600067YA/en unknown
- 2014-07-23 US US14/905,350 patent/US9856502B2/en active Active
- 2014-07-24 TW TW103125274A patent/TWI621711B/zh not_active IP Right Cessation
-
2016
- 2016-01-22 PH PH12016500158A patent/PH12016500158A1/en unknown
- 2016-02-18 ZA ZA2016/01113A patent/ZA201601113B/en unknown
-
2017
- 2017-11-21 US US15/819,351 patent/US10308970B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016525352A5 (cg-RX-API-DMAC7.html) | ||
| Abdeldaim et al. | Fc-engineered therapeutic antibodies: recent advances and future directions | |
| Van der Horst et al. | Fc-engineered antibodies with enhanced Fc-effector function for the treatment of B-cell malignancies | |
| JP6963665B2 (ja) | 細胞傷害誘導治療剤 | |
| Rodriguez-Nava et al. | Mechanisms of action and limitations of monoclonal antibodies and single chain fragment variable (scFv) in the treatment of cancer | |
| CN106967172B (zh) | 抗ctla4-抗pd-1 双功能抗体、其药物组合物及其用途 | |
| PE20210342A1 (es) | Anticuerpos anti-sirpa y metodos de utilizacion de los mismos | |
| RU2014130766A (ru) | Гуманизированное анти-эпирегулин-антитело и противораковый терапевтический агент, содержащий указанное антитело, в качестве активного ингредиента | |
| JP2012254083A5 (cg-RX-API-DMAC7.html) | ||
| TW202342540A (zh) | 用於癌之治療的細胞傷害誘導治療劑 | |
| KR20160056880A (ko) | 항garp 단백질 항체와 그 용도 | |
| CN106167525A (zh) | 筛选超低岩藻糖细胞系的方法和应用 | |
| CN107531793A (zh) | 对人类cd19具有专一性的抗体药剂和其用途 | |
| CN102373214A (zh) | 具有增加的Fc受体结合亲和性和效应子功能的CD20抗体 | |
| UA115533C2 (uk) | ГУМАНІЗОВАНЕ МОНОКЛОНАЛЬНЕ АНТИТІЛО, СПЕЦИФІЧНЕ ДО КОМПЛЕКСУ αβTCR/СD3 ЛЮДИНИ | |
| JP2014515598A (ja) | 二重特異性三鎖抗体様分子 | |
| TWI879694B (zh) | 抗ctla-4抗體的用途 | |
| WO2022242703A1 (zh) | 抗msln抗体及其应用 | |
| KR20230093010A (ko) | 신규 항-lilrb2 항체 및 유도체 생성물 | |
| TW202304997A (zh) | 新型抗ｃｄ４抗體 | |
| JP2015530989A5 (cg-RX-API-DMAC7.html) | ||
| Suzuki et al. | Anti-HER2 cancer-specific mAb, H2Mab-250-hG1, possesses higher complement-dependent cytotoxicity than trastuzumab | |
| CN116685604A (zh) | 抗人msln的抗体及其用途 | |
| Hart et al. | Human cell line-derived monoclonal IgA antibodies for cancer immunotherapy | |
| CN116847863A (zh) | 抗人cd22的单克隆抗体及其用途 |